Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells.

Oncotargetยท2026
Same author

Day case and inpatient elective thyroid lobectomy across England: observational study of variation in practice and safety.

The British journal of surgeryยท2026
Same author

The SCD1 inhibitor aramchol interacts with regorafenib to kill GI tumor cells <i>in vitro</i> and <i>in vivo</i>.

Oncotargetยท2025
Same author

GZ17-6.02 interacts with carboplatin and etoposide to kill neuroblastoma cells.

Anti-cancer drugsยท2025
Same author

Multi-Objective Design and Optimization of Hardware-Friendly Grid-Based Sparse MIMO Arrays.

Sensors (Basel, Switzerland)ยท2024
Same author

Retraction Notice to: Inhibition of Multiple Protective Signaling Pathways and Ad.5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma.

Molecular therapy : the journal of the American Society of Gene Therapyยท2024

Related Experiment Video

Updated: May 8, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

PARP inhibitors are not all equal.

Paul Dent1

  • 1Department of Neurosurgery; Massey Cancer Center; Virginia Commonwealth University; Richmond, VA USA.

Cancer Biology & Therapy
|September 13, 2013
PubMed
Summary

Poly (ADP-ribose) polymerase 1 (PARP1) is crucial for DNA repair and cell cycle regulation, not just apoptosis. PARP1 inhibitors show potential in specific breast cancer subtypes, warranting further investigation.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Background:

  • Poly (ADP-ribose) polymerase 1 (PARP1) is traditionally viewed as a caspase 3 substrate, indicating apoptosis.
  • However, PARP1 is fundamentally involved in DNA repair and cell cycle regulation.
  • PARP1 activation by damaged DNA facilitates DNA repair complex formation and cell cycle checkpoint activation.

Purpose of the Study:

  • To investigate the biological role and therapeutic potential of PARP1 inhibitors.
  • To examine PARP1 inhibitor efficacy across diverse breast cancer cell lines, including triple-negative subtypes.

Main Methods:

  • Cell line studies involving a range of triple-negative and non-triple-negative breast cancer models.
  • Analysis of PARP1 inhibitor biology within these cellular contexts.
Keywords:
CDK1PARP inhibitorsRO-3306breast canceriniparibolaparibtriple-negative

More Related Videos

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Related Experiment Videos

Last Updated: May 8, 2026

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
15:53

Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells

Published on: August 21, 2013

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader
07:13

Characterizing Modulators of Protease-Activated Receptors with a Calcium Mobilization Assay Using a Plate Reader

Published on: May 24, 2024

Main Results:

  • PARP1 plays a significant role in DNA repair and cell cycle progression.
  • PARP inhibitors have demonstrated limited efficacy as single agents, particularly in patients with functional BRCA1/2.

Conclusions:

  • PARP1's function extends beyond apoptosis, highlighting its importance in DNA repair and cell cycle control.
  • Further research into PARP1 inhibitor mechanisms and applications in breast cancer is warranted, especially in specific patient populations.